Longeveron to Present at the Virtual Life Sciences Investor Forum on June 20, 2024
Longeveron to Present at the Virtual Life Sciences Investor Forum on June 20, 2024
MIAMI, June 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, including hypoplastic left heart syndrome (HLHS) and Alzheimer's disease, today announced that it will participate in the Virtual Life Sciences Investor Forum taking place June 20, 2024.
2024年6月17日邁阿密（GLOBE NEWSWIRE）——Longeveron Inc.（納斯達克股票代碼：LGVN）是一家臨床階段的再生醫學生物技術公司，研發針對威脅生命和與衰老相關的慢性病症的細胞治療方案，包括低形態左心綜合症（HLHS）和阿爾茨海默病。今天宣佈，將於2024年6月20日參加虛擬生命科學投資者論壇。
Details for the Company's participation:
公司參與細節：
|
Fireside Chat Date: Fireside Chat Time: |
Thursday, June 20, 2024 10:30 a.m. ET |
| 爐邊聊天日期： 爐邊聊天時間： |
2024年6月20日星期四 美國東部時間上午10:30 |
The webcast for this conference presentation may be accessed at the "Events and Presentations" section of the Company's website. A replay of the webcast will be available on the Longeveron website for 90 days following the conference.
此次會議演講的網絡直播可以在公司網站的“事件和演示文稿”部分訪問。演示文稿的重播將在Longeveron網站上90天內提供。
About Longeveron Inc.
關於Longeveron Inc.：
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company's lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer's disease, and Aging-related Frailty. The Lomecel-BTM HLHS program has received three distinct and important U.S. FDA designations: Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation. For more information, visit or follow Longeveron on LinkedIn, X, and Instagram.
Longeveron是一家臨床階段的生物技術公司，開發再生醫學以解決未被滿足的醫學需求。公司的主要研究產品是Lomecel-B，一種從年輕健康成人的骨髓中分離出來的異基因藥物信號細胞（MSC）治療產品。Lomecel-B具有多種潛在機制，涵蓋促進血管、促進再生、抗炎、組織修復和癒合效應，廣泛應用於不同的疾病領域。Longeveron目前正在開展三個流水線指標：低形態左心綜合症（HLHS）、阿爾茨海默病和與衰老相關的虛弱。Lomecel-B HLHS項目已獲得三個不同且重要的美國FDA認證：孤兒藥物認證、快速通道認證和罕見兒科疾病認證。更多信息請訪問網站，或在LinkedIn、X和Instagram上關注Longeveron。此款超便攜式投影儀使用了最新的 Android TV 界面，而且遙控器還內置了 Google AssistantTM 功能，用戶可以非常方便地使用它。
Investor Contact:
投資者聯繫人：
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
Derek Cole
投資者關係諮詢解決方案
derek.cole@iradvisory.com
譯文內容由第三人軟體翻譯。